Connexion
E-mail
Mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON
  1. Accueil Zonebourse
  2. Actions
  3. Royaume-Uni
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Société
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
Métier
Logo AstraZeneca PLC
AstraZeneca PLC figure parmi les principaux groupes pharmaceutiques mondiaux. Le CA par source de revenus se répartit comme suit :

- ventes de produits (97,3%). Le CA par domaine thérapeutique se ventile entre oncologie (41,9%), maladies cardio-vasculaires, rénales et métaboliques (27,4%), maladies respiratoires et auto-immunes (20,7%) et autres (10% ; maladies inflammatoires, maladies neurologiques, maladies gastro-intestinales et maladies infectieuses) ;

- revenus de collaboration (2,7%).

La répartition géographique du CA est la suivante : Royaume Uni (6,5%), Europe continentale (18,2%), Amérique (38,7%) et Afrique-Asie-Australie (36,6%).

Nombre d'employés : 76 100 personnes.
Ventes par activité
20192020Delta
GBP (en Millions)%GBP (en Millions)%
Oncology6 79435.5%8 46139.3% +24.54%
Cardiovascular, Renal & Metabolism5 41328.3%5 53425.7% +2.22%
Respiratory4 22622.1%4 17719.4% -1.14%
Other Diseases2 03910.7%2 0179.4% -1.05%
Externalisation Revenue641,983.4%566,932.6% -11.69%
Ventes par région
2020
GBP (en Millions)%
United States6 98332.5%
China4 16819.4%
Japan2 0029.3%
United Kingdom1 3586.3%
Other Asia, Africa and Australasia1 1965.6%
Other Continental Europe1 0855%
Sweden800,093.7%
Germany730,693.4%
Other Americas593,442.8%
France509,222.4%
Dirigeants
Nom AgeDepuisTitre
Pascal Soriot602012Chief Executive Officer & Executive Director
Marc Dunoyer682013Chief Financial Officer & Executive Director
Menelas Pangalos-2019EVP-Biopharmaceuticals Research & Development
Pam Cheng492015Executive VP-Operations & Information Technology
Henry Cremisi--Medical Director
Katarina Ageborg-2017Chief Compliance Officer & EVP-Sustainability
Marcus Wallenberg641999Independent Non-Executive Director
Leif Johansson692012Non-Executive Chairman
Philip Arthur John Broadley592021Senior Independent Non-Executive Director
Nazneen Rahman, Dr.-2017Independent Non-Executive Director
Administrateurs
Nom AgeDepuisTitre
Leif Johansson692012Non-Executive Chairman
Marcus Wallenberg641999Independent Non-Executive Director
Marc Dunoyer682013Chief Financial Officer & Executive Director
Pascal Soriot602012Chief Executive Officer & Executive Director
Philip Arthur John Broadley592021Senior Independent Non-Executive Director
Nazneen Rahman, Dr.-2017Independent Non-Executive Director
Sherilyn McCoy612017Independent Non-Executive Director
Deborah DiSanzo602017Independent Non-Executive Director
Tony Mok, Dr.592019Independent Non-Executive Director
Michel Demaré642019Independent Non-Executive Director
Actions
Vote NombreFlottantAutocontrôleFlottant Total
Action A 1 1 312 762 006 1 256 906 517 95.7% 0 0.0% 95.7%
Actionnaires
Nom Actions%
Wellington Management Co. LLP 68 525 329 5,22%
Capital Research & Management Co. (World Investors) 56 102 804 4,27%
BlackRock Investment Management (UK) Ltd. 54 582 684 4,16%
Investor AB (Investment Company) 51 587 810 3,93%
The Vanguard Group, Inc. 34 955 607 2,66%
Norges Bank Investment Management 30 599 000 2,33%
BlackRock Fund Advisors 24 729 276 1,88%
BlackRock Advisors (UK) Ltd. 16 761 842 1,28%
Fidelity Management & Research Co. LLC 14 342 679 1,09%
SSgA Funds Management, Inc. 13 710 211 1,04%
Participations
Nom Actions%Valorisation
AstraZeneca Pharma India Limited (506820) 18 750 00075,0%771 964 875 USD
ADC Therapeutics SA (ADCT) 4 011 2155,23%97 913 758 USD
Silence Therapeutics plc (SLN) 4 397 2474,92%33 367 849 USD
Innate Pharma (IPH) 7 485 5009,48%32 797 868 USD
Circassia Group Plc (CIR) 71 081 21717,0%28 832 674 USD
PhaseBio Pharmaceuticals, Inc. (PHAS) 3 004 5546,28%10 395 757 USD
Pieris Pharmaceuticals, Inc. (PIRS) 3 584 2306,00%9 211 471 USD
Entasis Therapeutics Holdings Inc. (ETTX) 2 164 8555,80%4 632 790 USD
Places et indices
-
- Main Market
- OMX Stockholm 30 / FTSE 100, FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50
Codes boursiers
- Code Bloomberg :  AZN:LN
- Code Reuters :  AZN.L
- Code Datastream :  AZN
Coordonnées société
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA Cambridge, Cambridgeshire


Téléphone : +44 (0)20 3749 5000
Fax : +44 (0)20 7604 8151
Internet : https://www.astrazeneca.com/investor-relations.html
Portefeuille de Marques
En partenariat avec Mes Marques en Bourse
Plus de marques de AstraZeneca PLC
Secteur Pharmacies - Autres
Var. 1janvCapitalisation (M$)
ASTRAZENECA PLC7.21%144 632
JOHNSON & JOHNSON7.99%442 937
ROCHE HOLDING AG-2.57%286 340
PFIZER, INC.7.82%221 397
ABBVIE INC.8.82%203 045
NOVARTIS AG-4.30%197 785
MERCK & CO., INC.-3.80%197 501
NOVO NORDISK A/S12.23%178 793
ELI LILLY AND COMPANY15.46%175 624
AMGEN INC.9.09%144 115
BRISTOL-MYERS SQUIBB COMPANY4.03%144 085
SANOFI10.04%129 906
GLAXOSMITHKLINE PLC0.85%95 061
JIANGSU HENGRUI MEDICINE CO., LTD.-26.67%68 401
BAYER AG18.53%67 987
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-28.98%59 867
TAKEDA PHARMACEUTICAL COMPANY LIMITED-2.05%52 731
DAIICHI SANKYO COMPANY, LIMITED-23.78%47 622
CHANGCHUN HIGH & NEW TECHNOLOGY INDUSTRY (GROUP) INC.8.91%30 924
ASTELLAS PHARMA INC.4.45%28 222